Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge.

IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Infection and Drug Resistance Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI:10.2147/IDR.S485976
Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake
{"title":"Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge.","authors":"Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake","doi":"10.2147/IDR.S485976","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Repeat positive results for SARS-CoV-2 by antigen detection test/RT-PCR in recovered COVID-19 patients were not very rare even when omicron variants became dominant, but the clinical features of patients with recurrent COVID-19 during hospitalization are still unclear.</p><p><strong>Methods: </strong>The clinical characteristics of patients with recurrent COVID-19 during hospitalization were retrospectively investigated from January 2023 to December 2023.</p><p><strong>Results: </strong>Recurrence of COVID-19 was found in 7 of 275 (2.5%) patients during hospitalization. Their mean age was 80.3 (74-89) years, and 4 of 7 (57.1%) patients were hospitalized on the hematology ward with B cell/non-Hodgkin lymphoma. These 4 lymphoma patients had been vaccinated, but the other 3 patients hospitalized on the emergency ward and the neurology ward had not been vaccinated. Of the 7 patients, 6 (85.7%) were initially treated with remdesivir (RDV), but only 3 patients were re-treated with RDV, and the other 4 patients were successfully re-treated with oral 3C-like protease inhibitors, such as ensitrelvir (ESV) and nirmatrelvir/ritonavir (N/R).</p><p><strong>Conclusion: </strong>These data suggest that COVID-19 recurrence was found in patients with hematological disorders, such as lymphoma, and/or patients with no vaccination history. However, these patients were treated successfully by re-administration of anti-SARS-CoV-2 agents, including ESV and N/R.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"17 ","pages":"5011-5015"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568766/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S485976","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Repeat positive results for SARS-CoV-2 by antigen detection test/RT-PCR in recovered COVID-19 patients were not very rare even when omicron variants became dominant, but the clinical features of patients with recurrent COVID-19 during hospitalization are still unclear.

Methods: The clinical characteristics of patients with recurrent COVID-19 during hospitalization were retrospectively investigated from January 2023 to December 2023.

Results: Recurrence of COVID-19 was found in 7 of 275 (2.5%) patients during hospitalization. Their mean age was 80.3 (74-89) years, and 4 of 7 (57.1%) patients were hospitalized on the hematology ward with B cell/non-Hodgkin lymphoma. These 4 lymphoma patients had been vaccinated, but the other 3 patients hospitalized on the emergency ward and the neurology ward had not been vaccinated. Of the 7 patients, 6 (85.7%) were initially treated with remdesivir (RDV), but only 3 patients were re-treated with RDV, and the other 4 patients were successfully re-treated with oral 3C-like protease inhibitors, such as ensitrelvir (ESV) and nirmatrelvir/ritonavir (N/R).

Conclusion: These data suggest that COVID-19 recurrence was found in patients with hematological disorders, such as lymphoma, and/or patients with no vaccination history. However, these patients were treated successfully by re-administration of anti-SARS-CoV-2 agents, including ESV and N/R.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
奥米克隆变异突变住院期间 COVID-19 复发患者的临床特征。
背景:通过抗原检测试验/RT-PCR检测,COVID-19康复患者的SARS-CoV-2重复阳性结果并不罕见,即使在奥米克变异成为优势变异时也是如此,但住院期间复发COVID-19患者的临床特征仍不清楚:方法:回顾性调查了 2023 年 1 月至 2023 年 12 月住院期间复发 COVID-19 患者的临床特征:结果:275名患者中有7名(2.5%)在住院期间复发了COVID-19。他们的平均年龄为80.3(74-89)岁,7名患者中有4名(57.1%)因B细胞/非霍奇金淋巴瘤在血液科病房住院。这 4 名淋巴瘤患者都接种过疫苗,但在急诊病房和神经科病房住院的另外 3 名患者没有接种过疫苗。在这7名患者中,有6名(85.7%)最初接受了雷米替韦(RDV)治疗,但只有3名患者接受了RDV的再治疗,其他4名患者则成功接受了口服3C类蛋白酶抑制剂的再治疗,如恩西替韦(ESV)和尼尔马替韦/利托那韦(N/R):这些数据表明,在患有淋巴瘤等血液病和/或无疫苗接种史的患者中发现了 COVID-19 的复发。然而,这些患者通过再次使用抗SARS-CoV-2药物(包括ESV和N/R)获得了成功治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Infection and Drug Resistance
Infection and Drug Resistance Medicine-Pharmacology (medical)
CiteScore
5.60
自引率
7.70%
发文量
826
审稿时长
16 weeks
期刊介绍: About Journal Editors Peer Reviewers Articles Article Publishing Charges Aims and Scope Call For Papers ISSN: 1178-6973 Editor-in-Chief: Professor Suresh Antony An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
期刊最新文献
Coagulation Parameters in Elderly Patients with Severe Pneumonia: Correlation with Disease Severity and Prognosis. Utilizing Targeted Next-Generation Sequencing for Rapid, Accurate, and Cost-Effective Pathogen Detection in Lower Respiratory Tract Infections. Efficacy of Contezolid in the Treatment of Catheter-Related Bloodstream Infections Caused by Methicillin-Resistant Staphylococcus aureus in a Patient with Hepatorenal Syndrome and Acute Kidney Injury: A Case Report. Nanobubble Ozone Stored in Hyaluronic Acid-Decorated Liposome Solutions: Inactivating Antibiotic-Resistant Bacteria and Genotoxicity, Sub-Acute and Sub-Chronic Toxicity Tests. Risk Factor Analysis and Molecular Epidemiological Investigation of Carbapenem-Resistant Enterobacteriaceae (CRE) Infection in Patients with Acute Pancreatitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1